They also indicated that specific inflammatory pathways are involved in human ASCVD, and highlighted the role of NOD, LRR, and nod-like receptor protein 3 (NLRP3) inflammasome-associated pathways as effective therapeutic targets for ASCVD. This evidence concerns the gene NLRP3 and atherosclerosis.